Wednesday, September 28, 2022 11:02:29 AM
As far as I know, there is no other drug firm / bio-tech with a phase III drug trial with a market cap anywhere near as low as the $RVVTF MC.
The Risk reward makes this a screaming a buy... today...
And the FDA asked them to prepare for and officially request a meeting to discussing how best to move forward...
The FDA needs a Covid19 winner...
The Risk reward makes this a screaming a buy... today...
And the FDA asked them to prepare for and officially request a meeting to discussing how best to move forward...
The FDA needs a Covid19 winner...
Recent RVVTF News
- Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases • ACCESS Newswire • 03/11/2026 11:30:00 AM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 12/15/2025 12:30:00 PM
- Revive Therapeutics Provides Update of Key Nerve Agent Countermeasure Study • GlobeNewswire Inc. • 11/21/2025 05:07:49 PM
- Revive Therapeutics Announces Closing of Second Tranche of Private Placement • GlobeNewswire Inc. • 09/19/2025 09:00:28 PM
